http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-058055-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdd619b8a2cc2f110b9ee4dc8d896a17 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| filingDate | 2006-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-058055-A1 |
| titleOfInvention | PHENILETILAMINE ANALOGS AND ITS USE FOR THE TREATMENT OF GLAUCOMA |
| abstract | Phenylethylamine analogs useful for the treatment of glaucoma. Claim 1: Use of a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of the formula (1) wherein R1 and R2 are independently H or C1-4 alkyl; R3 and R4 are independently H, C1-4 alkyl, or R3, R4 and the C atom to which they are attached can form a cyclopropyl ring; Y is H, C1-4 alkyl, or OR5; R5 is H or C1-4 alkyl; A and B are independently OH, C1-3 alkoxy, OS (O) 2W, OC (= O) W, or OC (= O) NW2W3; W is C1-4 alkyl; W2 and W3 are independently H or C1-4 alkyl; X is CH (OH) R6, C (= O) R6, (CH2) nZ, or (CH2) mZ '; R6 is C1-4 alkyl, (CH2) m2SR8, or (CH2) m2OR8; n is 1-4; m is 2-4; m2 is 1-4; Z is OCF3, CN, S (O) n2R6, C (O) NR7R8, C (C = O) R6, CH (OH) R6, SO2NR7R8, NR6R9, CO2R6, S (O) n2CH2CH (OH) R6, S ( O) n2CH2C (= O) R6, S (O) n2CH2CO2R6, S (O) n2CH2C (= O) NR7R8, aryl, heterocyclyl, or heteroaryl; Z 'is OH or OR6; n2 is 0 or 1; R7 is H, C1-4 alkyl, OH, or OCH3; and R8 and R9 are independently H or C1-4 alkyl, to decrease and control normal or elevated IOP. Claim 4: Use of claim 1 wherein the composition is an ophthalmic composition administered topically and the pharmaceutically effective amount of the compound is 0.1-2% (w / v). |
| priorityDate | 2005-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394295 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974 |
Total number of triples: 17.